Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 15/20 | 0.46 |
| ▸ | CCNK | O75909 | 1/20 | 0.44 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3733689 | 0.89 | GLS (0.48) | WNT3ATBK1CCNKCDK12MEN1 | |
| SCHEMBL3738423 | 0.87 | NAMPT (0.43) | KMT2ANAMPT | |
| SCHEMBL3728897 | 0.87 | KDR (0.47) | WNT3AMEN1KMT2ANAMPT | |
| SCHEMBL3734324 | 0.86 | MEN1 (0.44) | WNT3ATBK1CCNKCDK12MEN1 | |
| SCHEMBL3735920 | 0.86 | TBK1 (0.45) | WNT3ATBK1CCNKCDK12MEN1 | |
| SCHEMBL3734772 | 0.82 | NAMPT (0.47) | MEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL399180 | 0.81 | TBK1 (0.46) | WNT3ATBK1CCNKCDK12MEN1 | |
| SCHEMBL7859141 | 0.81 | MEN1 (0.45) | WNT3ATBK1CCNKCDK12MEN1 | |
| SCHEMBL3739068 | 0.80 | EPHX2 (0.47) | WNT3AMEN1MAPTTSHRKMT2A | |
| SCHEMBL3731787 | 0.80 | NAMPT (0.45) | MEN1KMT2ASMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | claimed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-7825120-B2 | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas | CYTOKINETICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-1959963-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20070197504-A1 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007089336-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197504-A1 | Certain chemical entities, compositions and methods | TNNI3, TNNT2, MYLK2 | WNT3A 4128/4885TBK1 2626/4885CCNK 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.